Mitomycin C plus capecitabine (MiXe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2871-2875

  Maisano, Roberto ^a,d   Caristi, Nicola ^b   Mare, Marzia ^c   Raffaele, Mario ^a   Iorfida, Monica ^b   Mafodda, Antonino ^c   Zavettieri, Maria ^a   Nardi, Mario ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Istituto Oncologico del Mediterraneo   (Italy)

^d NONE   (Italy)

Author keywords

Capecitabine; Metastatic breast cancer; Mitomycin C

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTHRACYCLINE DERIVATIVE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; FLUOROURACIL; FULVESTRANT; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 34547767714     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Seidman AD, O'Shaughnessy J and Missett J-L: Single-agent capecitabine a reference treatment for taxane-pretreated metastatic breast cancer? The Oncologist 7(suppl 6): 20-28, 2002.
2. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel- refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999.
3. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 92: 1759-1768, 2001.
4. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M and Luck HJ: Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with taxane-containing therapy. Ann Oncol 14: 1227-1233, 2003.
5. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillermin E, Morere JF, Montestrut F, Mouri Z and Namer M: Multicenter phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536-542, 2004.
6. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y and Mjaaland I: Oral capecitabine in anthracycline-and taxane pretreated advanced/metastatic breast cancer. Acta Oncologica 43: 186-189, 2004.
7. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzyme concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
8. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitusuka H: Positive correlation between the efficacy of capecitabine activities in tumors in human cancer xenografts. Cancer Res 58: 685-690, 1998.
9. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K and Ishitusuka H: Cytokines induce thymidine phosphorylase expression in tumors cells and make them more susceptible to 5-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993.
10. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka M: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
11. Ogata Y, Matono K, Sasatomi T, Ishibashi N, Torigoe S, Fukumitsu T, Mizobe T, Yamashita N, Yanagawa T and Shirouzu K: Upregulation of thymidine phosphorylase in rectal cancer tissue by mitomycin C. J Surg Oncol 93: 47-55, 2006.
12. Bartsch HH, Blossey HC and Nagel GA: Mitomycin C and high dose medroxyprogesterone acetate in the therapy of metastasing breast cancer. Results of a phase II study of Workshop for Internal Oncology of the German Cancer Association. Onkologie 5: 249-257, 1982.
13. Kennedy KA, Rochwell S and Sartorelli AC: Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40: 2356-2360, 1980.
14. Francini G, Petrioli R, Messinese S, Pozzessere D, Marsili S, Correale P, Sabatino M and Fiaschi AI: Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. Cancer Chemother Pharmacol 50: 271-276, 2002.
15. Maisano R, Caristi N, Mare M, Mafodda A, Carboni R, Montalto E, Iorfida M and Nardi M: Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study. Anticancer Res 25: 4513-4518, 2005.
16. National Cancer Institute: Cancer Therapy Evaluation Program: Common Toxicity Criteria. Http://ctep.cancer.gov/ reporting/ctc.html
17. Simon R, Wittes RE and Ellemberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381, 1985.
18. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
19. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V and Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
20. Pusztai L, Zhen J H, Aran B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL and Hortobagyi GN: Phase I and II Study of Exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21: 3454-3461, 2003.
21. Scartozzi M, Falcone A, Pucci F, Braconi C, Pierantoni C, Cavanna L, Franciosi V, Berardi R, Beretta G, Masi G, Allegrini G, Zaniboni A, Labianca R and Cascinu S: Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori 92: 384-388, 2006.
22. Rimassa L, Gullo C, Carnaghi C, Abbadessa G, Zuradelli M, Tronconi MC, Pressiani T and Santoro A: Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori 92: 285-289, 2006.
23. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J and Tebbut N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93: 510-514, 2005.
24. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JM, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK and Park K: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56: 10-14, 2005.
25. Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J and Shellito P: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 91: 839-843, 2004.
26. Hofheinz RD, Hartmann JT, Wilier A, Oechsle K, Hartun G, Gnad U, Saussele S, Kreil S, Bokemeyer C, Hehlmann R and Hochhaus A: Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer 91: 839-843, 2004.
27. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MB, Zepponi L, Santini D, Tonini G and Burattini L: Capecitabine and mitomycin C is an effective combination for anthracycline-and taxane-resistant metastatic breast cancer. Oncology 70: 294-300, 2006.
28. Geyer CE, Forster J, Lindquist D Chan S, Romieu CG, Pienkowsky T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S and Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743, 2006.